Tags : COMBI-AD Study

Novartis Reports Results of Dual regimen in P-III COMBI-AD Study

Tuba Khan September 17, 2020

Shots: The P-III COMBI-AD study involves assessing of Tafinlar (dabrafenib, 150mg, bid) + Mekinist (trametinib, 2mg, qd) vs two PBOs in patients with stage III, BRAF V600E/K-mutant melanoma without prior […]readmore

Tags : COMBI-AD Study

Novartis Reports Results of Dual regimen in P-III COMBI-AD Study

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : COMBI-AD Study

Novartis Reports Results of Dual regimen in P-III COMBI-AD Study

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company